SYRA HEALTH CORP - CLASS A (SYRA) Fundamental Analysis & Valuation

NASDAQ:SYRA • US87168W2035

0.1043 USD
-0.02 (-17.94%)
At close: Apr 17, 2025
0.0805 USD
-0.02 (-22.82%)
After Hours: 4/17/2025, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SYRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, SYRA scores 2 out of 10 in our fundamental rating. SYRA was compared to 101 industry peers in the Health Care Providers & Services industry. The financial health of SYRA is average, but there are quite some concerns on its profitability. SYRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. SYRA Profitability Analysis

1.1 Basic Checks

  • In the past year SYRA has reported negative net income.
  • In the past year SYRA has reported a negative cash flow from operations.
  • In the past 5 years SYRA always reported negative net income.
  • SYRA had a negative operating cash flow in each of the past 5 years.
SYRA Yearly Net Income VS EBIT VS OCF VS FCFSYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -102.17%, SYRA is doing worse than 94.29% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -130.59%, SYRA is doing worse than 80.95% of the companies in the same industry.
Industry RankSector Rank
ROA -102.17%
ROE -130.59%
ROIC N/A
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SYRA Yearly ROA, ROE, ROICSYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • SYRA has a Gross Margin (20.71%) which is in line with its industry peers.
  • SYRA's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SYRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
SYRA Yearly Profit, Operating, Gross MarginsSYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. SYRA Health Analysis

2.1 Basic Checks

  • SYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SYRA has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for SYRA is higher compared to a year ago.
SYRA Yearly Shares OutstandingSYRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SYRA Yearly Total Debt VS Total AssetsSYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

  • SYRA has an Altman-Z score of -2.79. This is a bad value and indicates that SYRA is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.79, SYRA is doing worse than 85.71% of the companies in the same industry.
  • A Debt/Equity ratio of 0.05 indicates that SYRA is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.05, SYRA is doing good in the industry, outperforming 78.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -2.79
ROIC/WACCN/A
WACC8.73%
SYRA Yearly LT Debt VS Equity VS FCFSYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • A Current Ratio of 5.46 indicates that SYRA has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 5.46, SYRA belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
  • SYRA has a Quick Ratio of 5.46. This indicates that SYRA is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 5.46, SYRA belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.46
Quick Ratio 5.46
SYRA Yearly Current Assets VS Current LiabilitesSYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SYRA Growth Analysis

3.1 Past

  • SYRA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.98%.
  • Looking at the last year, SYRA shows a very strong growth in Revenue. The Revenue has grown by 44.67%.
  • The Revenue has been growing by 78.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SYRA Yearly Revenue VS EstimatesSYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2M 4M 6M 8M
SYRA Yearly EPS VS EstimatesSYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. SYRA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SYRA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRA Price Earnings VS Forward Price EarningsSYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRA Per share dataSYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SYRA Dividend Analysis

5.1 Amount

  • No dividends for SYRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SYRA Fundamentals: All Metrics, Ratios and Statistics

SYRA HEALTH CORP - CLASS A

NASDAQ:SYRA (4/17/2025, 8:00:00 PM)

After market: 0.0805 -0.02 (-22.82%)

0.1043

-0.02 (-17.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-11
Earnings (Next)05-07
Inst Owners6.21%
Inst Owner Change0%
Ins Owners0.62%
Ins Owner Change0%
Market Cap1.18M
Revenue(TTM)7.98M
Net Income(TTM)-3.76M
AnalystsN/A
Price Target1.84 (1664.14%)
Short Float %0.61%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.36%
Min Revenue beat(2)-2.21%
Max Revenue beat(2)10.93%
Revenue beat(4)3
Avg Revenue beat(4)9.8%
Min Revenue beat(4)-2.21%
Max Revenue beat(4)22.54%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.71
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -102.17%
ROE -130.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.71%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
F-Score4
Asset Turnover2.17
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.7%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.46
Quick Ratio 5.46
Altman-Z -2.79
F-Score4
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)287.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.27%
OCF growth 3YN/A
OCF growth 5YN/A

SYRA HEALTH CORP - CLASS A / SYRA FAQ

What is the ChartMill fundamental rating of SYRA HEALTH CORP - CLASS A (SYRA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SYRA.


Can you provide the valuation status for SYRA HEALTH CORP - CLASS A?

ChartMill assigns a valuation rating of 0 / 10 to SYRA HEALTH CORP - CLASS A (SYRA). This can be considered as Overvalued.


How profitable is SYRA HEALTH CORP - CLASS A (SYRA) stock?

SYRA HEALTH CORP - CLASS A (SYRA) has a profitability rating of 0 / 10.


How financially healthy is SYRA HEALTH CORP - CLASS A?

The financial health rating of SYRA HEALTH CORP - CLASS A (SYRA) is 4 / 10.